Objectives: Direct comparison of different diseases allows clinicians and researchers to place the burden of symptoms and impact on quality of life of each condition in context. Generic health-related quality-of-life assessment tools allow such analysis, and limited data are available for British patients with chronic rhinosinusitis.
| INTRODUCTION
There is accumulating evidence of the personal and societal impact of chronic rhinosinusitis (CRS) with regard to symptom severity, 1 reduced productivity and absenteeism. 2 Many studies of patients with CRS increasingly use the Sinonasal Outcome Test (SNOT-22)
(disease-specific, internationally validated questionnaire) as an outcome measure. 3 While this allows for excellent assessment and monitoring of the impact of CRS symptoms at an individual level, it does not allow direct comparison with other chronic conditions.
Generic health-related quality-of-life (HRQoL) assessment tools allow comparison of disease states on both a functional level 4 and with regard to and the burden to society each condition presents. Such tools include the EuroQoL Five Dimension tool (EQ-5D-3L/5L), 5 Health Utilities Index, 6 the Short Form 36 (SF-36) 7 and the latter's shortened versions, the SF-12 and SF-6D.
Lange et al. published health utility assessments from the transEuropean GALEN study that showed a lower health-related quality of life using the EQ-5D-3L in CRS patients compared to those without CRS. 8 A recent study in the USA reported a lower health utility value (also generated by the EQ-5D) for patients with CRS compared to the general population, the value was similar to that of other chronic diseases such as mild asthma and migraine. 9 A large UK epidemiological study recently showed those with CRS to have lower QOL using the SF-36, specifically both mental health and emotional domains were lower. 10 The SF-36 was converted to a shorter form, the SF-12 and validated for use within the UK. 11 The SF-12 has itself been used for CRS patients outside the UK, 12 and as a short and quicker method of assessing HRQoL than the SF36, it is potentially more attractive for future research. Thus, the aim of this study was to evaluate the EQ-5D-5L and SF-12 health utility measures in a UK CRS population. In addition, the data can be seen alongside the widely published disease-specific SNOT-22 questionnaire.
| ME TH ODS
As part of a feasibility study, a prospective cohort of patients were recruited from six UK centres with a confirmed diagnosis of CRS without nasal polyps (CRSsNPs) just prior to commencing maximal medical therapy. 13 The study was ethically approved by the West 
| Measures
The SNOT-22 is an internationally validated disease-specific questionnaire detailing both disease-specific (e.g blocked nose) and global (e.g sleep disturbance) domains. The EQ-5D-5L is a standardised measure of health status consisting of a visual analogue scale (VAS) to assess patient-reported health state on the day of completing the survey (0=worst imaginable health state and 100=best imaginable health state) in addition to a questionnaire with five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) (EuroQol 2011). 16 Each of the dimensions asks for a response that corresponds to a health status level of no problems, slight problems, moderate problems, severe problems and extreme problems that are coded level 1-5, respectively. The levels can then converted into a health index score using the website (https://www.ohe.org/publications/valuinghealth-related-quality-life-eq-5d-5l-value-set-england), according to the population setting (in this case UK), on a scale where 1 equals perfect health and 0 equals death, and values less than zero represent states worse than death.
All three questionnaires were completed by patients at baseline, 12 weeks and 6 months, but for the purpose of this analysis which aimed to report HRQoL for British CRS patients only baseline data are reported.
| Analysis
51% were male. Following exclusions, 52 patients who completed all three questionnaires were included in this study. and the mean PCS 46 (SD of 11.46), both lower than the score expected for a "typical adult" (e.g score of 50 or above).
The EQ-5D has two components, the questionnaire given an index score and the VAS. The mean index score of was 0.75 (SD of 0.23). The questionnaire component is reported as the percentage of patients reporting a particular level within each of the five dimensions and is represented in Table 1 . The mean VAS score was 73.38.
Worse (higher) SNOT-22 scores were associated with lower EQ-5D-5L VAS and utility scores and SF-12 MCS and PCS scores (Figure 1) . In all cases, the coefficient on SNOT-22 score was statistically significant and negative (all four P-values on the SNOT-22 score regression coefficient <.05). Overall the SF-12 scores suggest that despite their CRS, patients manage relatively well with regard to both physical and mental quality-of-life components when compared to other chronic diseases (see Table 2 ). The findings from this study are in contrast with work by Glicklich et al. 19 and Erskine et al. 10 who used the full SF-36. In the later study overall scores were reduced in CRS patients when compared to non-CRS controls, with a difference of 11-17 points (P<.001) for overall quality of life. In their study, a significant difference was also found when looking at the mental and emotional health domains; those with CRS scored more negatively than those without, with those with CRSsNPs scoring more poorly than those with nasal polyps. Qualitative interviews have also found significant negative quality of life-related issues. There are several reasons for the discrepancy; it may be that the SF-12 lacks the sensitivity to detect the impact of CRS on the HRQoL of the patient, as the tool focuses largely on physical activity and mobility. One common problem for patients relating to quality of life is known to be accessing appropriate treatment, and the feeling that symptoms are not taken seriously hence there may therefore be benefit for the patients in the trial in knowing they are receiving treatment while taking part in a trial. Additionally, concurrent asthma contributes negatively on quality of life in CRS, at the main recruiting site of our study 16% of the 38 patients were found to have asthma compared with 21% in the more broadly inclusive CRES study 20 which may explain some of the difference in QoL.
EQ-5D-5L suggests there is a greater impact on CRS as the health index score generated for this group of patients was 0.75. We are limited by the lack of UK studies that use the newest version of the EQ-5D (5 level version as used in this study) when putting this figure into context. Data from the USA shows patients with COPD to have an index score of 0.79 21 and European data showed a score of 0.69 in patients 4 months after a stroke 22 Hence, our study would suggest that CRS does impact on quality of life and perhaps surprisingly to similar scale as that seen in other chronic disease states.
Health profile reporting shows that many patients are able to continue about their normal activities of daily living with the majority reporting a level 1 response of "no problem" with regard to mobility, self-care and usual activities. Contrary to this patients were more affected in the domains of pain/discomfort and anxiety/ depression with a larger percentage reporting a level 2 (slight problems) or 3 (moderate problems). This is of interest on two accounts, first similar to the aforementioned studies there appears to be a psychological aspect to the disease that is not particularly highlighted with the SF-12. Secondly, that pain/discomfort is reported in a significant number of patients in line with previous studies which have shown that 70% of patients with CRSsNPs undergoing sinus surgery report facial pain 23 alongside higher rates of anxiety and depression. 10 It is interesting that the health index score for our UK cohort of patients undergoing a trial of medical treatment suggests greater disease burden than a US cohort of patients who have already failed medical therapy and have been selected for surgery (index value of 0.81) 9 but may reflect differences in accepted maximum medical T A B L E 1 Percentage of patients reporting each level (no problems=level 1, extreme problem=level 5) of the five dimension components of the EQ-5D
Mobility Self-care therapy between the two nations. In our feasibility study, 50% of patients improved with maximal medical treatment, 13 and therefore, one would expect those selected for surgery in the US study to be a more severely affected subgroup. Of note, surgical intervention rates in the USA are significantly higher than in the UK and may reflect lower thresholds for surgery in the USA. In addition, it may also reflect differences in primary care treatment, such that only more severely affected patients are treated within secondary care in the UK. This highlights the importance of evaluating health utility in a UK cohort and puts the disease in perspective as compared to other commonly encountered chronic disease states.
| Strengths of this study
These study data are useful in two ways: firstly, it provides a reference generic QOL measurement in UK patients with CRS for future researchers. We have shown the mean SNOT-22 scores to be in line with a large UK epidemiological study, 24 and hence, the data provided here can be used as a benchmark for future patient cohorts.
Additionally, they allow comparison of CRSsNPs with other chronic disease states, the health index scores obtained from the EQ-5D
data indicate it has a significant impact on patients. The health index score generated for this group of patients gives a simple value in which to compare other CRS cohorts internationally but also allows comparison with other chronic disease states.
A recent European study found a prevalence of CRS to be at 11%, but despite comparable prevalence rates of both asthma and diabetes M:\scanning\W3G\COA\12903\new\1.tif with similar negative impact on quality of life and economic burden, there is a considerable disparity in the research funding and publications rates between the conditions. We would hope that the data would support future research into treatments for CRS on par with that for chronic respiratory disease and back pain. Making comparisons to other chronic conditions puts the plight of CRS patients into perspective.
PCS MCS
The fact that patients included in this study presented to a specific rhinology clinic (rather than a general ENT outpatient clinic) is a limitation of the study as it means there may be a bias towards those with more severe disease. However, due to the similar SNOT-22 scores to other CRSsNPs patients in larger cohorts 24, 25 and because the exclusion criteria prevented those who had tried previous maximal medical therapy from joining the study (therefore unlikely to have had recalcitrant disease), we believe the patients included here to be representative. Time from diagnosis will have varied in the group and some patients within the cohort will have received longer courses of intranasal steroids than others; while this may influence the baseline readings in our study, it is likely to reflect the general cohort of CRS patients worldwide who have often taken over-the-counter regimes alongside physician prescribed medications during their disease pathway. Other limitations include the small sample size and lack of data from patients with CRS with nasal polyposis, which should be performed in the future.
| Clinical applicability of the study
Index value generated from the EQ-5D questionnaire shows UK patients with CRSsNPs to be negatively affected with regard to their HRQoL with scores in line with other chronic disease states. We would advise using the EQ-5D-5L questionnaire, as a quick and reliable method of assessing HRQoL in future studies using CRS cohorts.
The SF-12 has not been shown on this occasion to be particularly useful and as such we would not advise it is used in CRS related studies but perhaps replaced by the SF-36 as used in other studies.
